
Tom Hemming Karlsen
- Professor, Research Head; MD, PhD
EDUCATION
1997: MD University of Bergen
2007: PhD University of Oslo
NORWEGIAN CLINICAL SPECIALIST ACCREDITATIONS
"Indremedisin" (Internal medicine) and "Fordøyelsessykdommer" (Gastroenterology)
PRESENT POSITIONS
- Research Head, Division of Surgery and specialized medicine, Oslo University Hospital.
- Full professor of internal medicine, University of Oslo.
- Senior consultant, Department of Transplantation Medicine, Oslo University Hospital Rikshospitalet.
RESEARCH GROUP
https://www.ous-research.no/nopsc/
http://www.med.uio.no/klinmed/english/research/groups/primary-sclerosing-cholangitis/
https://www.ous-research.no/riim/
PUBLISHED PROFILES
Pinzani M (2024) A Nordic Hygge and a World Vision. Journal of Hepatology 81:4-5.
Watts G (2022) Tom Hemming Karlsen: hepatologist with a public health message. Lancet 399:18.
Main Previous Positions | |
2012-2014 | Full Professor of Gastroenterology, UiB |
2007-2012 | Executive Manager, Norwegian PSC research center, UiO/OUH |
2007-2014 | M.D., Internal Medicine and Gastroenterology, OUH |
2004-2006 | PhD fellow, Institute of Immunology, UiO |
1999-2003 | M.D., Internal Medicine and Gastroenterology, Sørlandet Hospital Arendal |
Honors (selected items) | |
2024 | European Association for the Study of the Liver Recognition Award |
2024 | Klatskin-Boyer Lectureship in Hepatology (Yale School of Medicine) |
2019 | Elected member of the Norwegian Academy of Science and Letters |
2015 | International Hans Popper Award |
2013 | Oslo University Hospital Early Career Award |
2012 | United European Gastroenterology (UEG) Association Rising Star Award |
Commissions of trust (selected items) | |
2024- | Co-editor, Journal of Hepatology |
2024- | President Elect, the Biomedical Alliance in Europe (https://www.biomedeurope.org) |
2020-2023 | Board member, the Biomedical Alliance in Europe (https://www.biomedeurope.org/) |
2019-2023 | Board member, European Reference Network (ERN) for Rare Liver Diseases |
2019-2024 | Associate Editor, Journal of Hepatology |
2019-2021 | Board member, the University of Oslo “UiO:Life Science” |
2019-2021 | Co-chair, The Lancet-EASL Commission on Liver Disease in Europe |
2018-2022 | Chairman of the Board, Norwegian Center of Excellence “Hybrid Technology Hub” |
2017-2019 | Secretary General (Chairman), European Association for the Study of the Liver (EASL) |
2016-2021 | Member, Scientific Advisory Board, Carlos foundation, Mayo Clinic Rochester, US |
2014-2017 | Vice Secretary and Board member, EASL (www.easl.eu) |
2006-2014 | Coordinator, Nordic Liver Transplant Registry (www.scandiatransplant.org) |
Institutional Responsibilities (selected items) | |
2024- | Member of “Regionalt forskningsutvalg” (Research Council) in Helse Sør-Øst |
2024 | Working group participant, Oslo Science City “gravitation theme" of Health and Life sciences |
2024 | Working group participant, update of the personalized medicine strategy at OUH (hospital level) |
2022 | Internship Norwegian Ministry of Health (part time, August-December) |
2021- | Reference group University of Oslo "UiO:Life Science" |
2019-2021 | Project leader, Implementation of Personalized Medicine at OUH (hospital level) |
2015-2019 | Member of “Forskningsutvalget” (Research Council), hospital level (OUH) |
2017-2018 | Working group for action plan “Personalized medicine”, Norwegian Research Council |
2010-2016 | Member of “Forskningsutvalget” (Research Council), division level (KKT, OUH) |
2015-2016 | National project group for personalized medicine, Norwegian Directorate for Health |
2010-2014 | Member of “Biobankutvalget” (Biobank Council) hospital level (OUH) |
2009 | Working group for “action plan for biobank and registries” in Helse Sør-Øst |
2001-2002 | Project leader, electronic patient records evaluation, Norwegian Health Directorate |
1994-1996 | Establishing of small group educational activities, Faculty of Medicine, UiB |
SELECTED PUBLICATIONS
Karlsen TH, Rutter H, Carrieri P, et al. (2024) The EASL-Lancet Commission on liver health in Europe: prevention, case-finding, and early diagnosis to reduce liver-related mortality. Lancet 403:1522-1524.
COVID-19 Host Genetics Initiative (2023) A second update on mapping the human genetic architecture of COVID-19. Nature 621:E7-E26
Serra-Burriel M, Juanola A, Serra-Burriel F, et al. (2023) Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study. Lancet 402:988-996.
Karlsen TH (2022) Understanding COVID-19 through genome-wide association studies. Nature Genetics 54:368-369.
Karlsen TH, Sheron N, Zelber-Sagi S, et al. (2022) The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 399:61-116.
COVID-19 Host Genetics Initiative (2021) Mapping the human genetic architecture of COVID-19. Nature 600:472-477.
Thaventhiran JED, Lango Allen H, Burren OS et al. (2020) Whole-genome sequencing of a sporadic primary immunodeficiency cohort. Nature 583:90-95.
Ellinghaus D, Degenhardt F, Bujanda L et al. (2020) Genomewide Association Study of Severe Covid-19 with Respiratory Failure. New England Journal of Medicine 383:1522-1534.
Melum E, Jiang X, Baker KD, et al. (2019) Control of CD1d-restricted antigen presentation and inflammation by sphingomyelin. Nature Immunology. 20, 1644-1655.
Schneditz G, Elias JE, Pagano E, et al. (2019) GPR35 promotes glycolysis, proliferation, and oncogenic signaling by engaging with the sodium potassium pump. Science Signaling, 562, eaau9048.
Manns MP, Burra P, Sargent J, Horton R, Karlsen TH (2018) The Lancet-EASL Commission on liver diseases in Europe: overcoming unmet needs, stigma, and inequities. Lancet, 10148, 621-622.
Sampaziotis F, Justin AW, Tysoe OC et al. (2017) Reconstruction of the mouse extrahepatic biliary tree using primary human extrahepatic cholangiocyte organoids. Nature Medicine, 23, 954-963.
Ji SG, Juran BD, Mucha S, et al. (2017) Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nature Genetics, 49, 269-273.
Wang J, Thingholm LB, Skiecevièienë J, et al. (2016) Genome-wide association analysis identifies variation in vitamin D receptor and other host factors influencing the gut microbiota. Nature Genetics, 48,1396-1406.
Ellinghaus D, Jostins L, Spain SL, et al. (2016) Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Nature Genetics, 48, 510-8.
Sampaziotis F, Cardoso de Brito M, Madrigal P, et al. (2015) Cholangiocytes derived from human induced pluripotent stem cells for disease modeling and drug validation. Nature Biotechnology, 33,845-52.
Goyette P, Boucher G, Mallon D, et al. (2015). High density mapping of the MHC reveals a common role for HLADRB1* 01:03 in IBD and heterozygous advantage in ulcerative colitis; Nature Genetics, 47 (2), 172-179.
Hirschfield GM, Karlsen TH, Lindor K, Adams D, (2013). Primary sclerosing cholangitis; Lancet, 382 (9904), 1587-99.
Liu JZ, Hov JR, Folseraas T, et al., (2013). Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis; Nature Genetics, 45 (6), 670-5.
Jostins L, Ripke S, Weersma RK, et al., (2012). Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease; Nature, 491 (7422), 119-24.
Anderson CA, Boucher G, Lees CW, et al., (2011). Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47; Nature Genetics, 43 (3), 246-52
Melum E, Franke A, Schramm C, et al., (2011). Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci; Nature Genetics, 43 (1), 17-9
Ellinghaus E, Ellinghaus D, Stuart PE, et al., (2010). Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2; Nature Genetics, 42 (11), 991-5
Franke A, Balschun T, Sina C, et al., (2010). Genome-wide association study for ulcerative colitis identifies risk loci at 7q22 and 22q13 (IL17REL); Nature Genetics, 42 (4), 292-4
Franke A, Balschun T, Karlsen TH, et al. (2008). Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility; Nature Genetics, 40 (11), 1319-23
Franke A, Balschun T, Karlsen TH, et al. (2008). Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis; Nature Genetics, 40 (6), 713-5